Supernus v. Creekwood: Qelbree Viloxazine ANDA Litigation Consolidated in NJ
Supernus Pharmaceuticals sued Creekwood Pharmaceuticals over six Orange Book-listed patents protecting Qelbree (viloxazine extended-release capsules), an ADHD treatment. Within 165 days, the New Jersey District Court consolidated this action with cases against 13 generic defendants — one of the broader multi-party ANDA consolidations in recent pharma litigation.
Six-Patent Qelbree Battle Draws 14 Generic Challengers into One NJ Proceeding
Supernus Pharmaceuticals filed this action in the District of New Jersey on July 11, 2025, alleging infringement of six patents listed in the FDA Orange Book for Qelbree — viloxazine extended-release capsules in 100 mg, 150 mg, and 200 mg strengths. The asserted patents span formulation and method-of-use claims across application numbers ranging from US13/761757 to US17/896774, reflecting a layered IP portfolio built over more than a decade of Qelbree development. The defendant, Creekwood Pharmaceuticals, LLC, had filed an ANDA (Abbreviated New Drug Application) seeking generic approval for 100 mg and 200 mg viloxazine ER capsules.
On December 23, 2025, the court issued a Consolidation Order, formally merging this action with parallel ANDA cases brought against 13 other generic defendants — including Apotex, Aurobindo, Zydus, MSN Pharmaceuticals, Macleods, Biophore, and others. Consolidation for pretrial purposes means all defendants will face the same schedule, discovery framework, and pre-trial rulings, streamlining what would otherwise be duplicative proceedings. The underlying infringement claims remain active; consolidation does not resolve the merits.
The 165-day path from filing to consolidation order is consistent with efficient ANDA multi-defendant management in New Jersey, a forum experienced in Hatch-Waxman litigation. The breadth of the defendant class — 14 generic companies — suggests widespread generic interest in viloxazine ER, a CNS compound used for ADHD. The public record does not yet disclose claim construction positions, any inter partes review filings by defendants, or settlement negotiations, all of which typically shape the ultimate resolution of large-scale ANDA consolidations.
Filing to Case Consolidated in 165 days
165 days from filing to consolidation order — rapid procedural resolution typical of ANDA multi-defendant coordination
Case consolidated: what the court’s order means for Supernus and all defendants
Consolidation is procedural — the merits fight continues
A consolidation order under Fed. R. Civ. P. 42(a) merges separate actions sharing common questions of law or fact. Here, all 14 defendants face the same six Qelbree patents on the same Hatch-Waxman infringement theory. Consolidation creates a single pretrial schedule and reduces duplicative discovery — it does not dismiss any claims or resolve infringement or validity. All defendants remain parties and retain their individual defenses.
Procedural — merits unresolvedSupernus gains efficient enforcement across all 14 challengers
Consolidation typically favours the patent holder in large ANDA disputes. Supernus can pursue claim construction and invalidity defenses once across all defendants rather than 14 times. This reduces cost, prevents inconsistent rulings, and lets Supernus present its strongest infringement case in a single coordinated proceeding. The 30-month stay protection under Hatch-Waxman continues to run, maintaining Qelbree’s exclusivity period during litigation.
Efficient multi-front enforcementGeneric defendants face a coordinated litigation schedule
For Creekwood and co-defendants, consolidation means shared discovery and coordinated briefing — which can reduce individual costs but also limits tactical flexibility. Defendants with distinct invalidity theories or claim construction positions may need to coordinate with parties whose interests only partially align. Any adverse ruling on claim construction will bind all consolidated defendants simultaneously, raising the stakes of each pretrial decision.
Coordinated defense required14-party ANDA wave signals high commercial value of Qelbree franchise
The scale of generic challenger interest — 14 defendants across a single consolidation — is consistent with a commercially significant branded product. Viloxazine ER is an ADHD therapy with a distinct CNS mechanism, and generic entry would substantially erode Supernus’s revenue. The consolidated proceeding will produce claim construction rulings that govern all challengers simultaneously, making this litigation a high-stakes bellwether for the entire Qelbree IP estate.
High-value ADHD franchise at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | Specialty CNS pharmaceutical company — holder of US12121523B2 and 5 further Qelbree patentsSearch in Eureka ↗ |
| Defendant | CREEKWOOD PHARMACEUTICALS, LLC | Company | Generic pharmaceutical manufacturer seeking ANDA approval for viloxazine extended-release capsulesSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EDGAR H. HAUG | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JONATHAN HERSTOFF | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | KAITLIN M. FARRELL | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | NICHOLAS F. GIOVE | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Frank Kurz | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Haug Partners, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant counsel | HANA JEONG PAK | Attorney | Counsel for CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant counsel | KEVIN M. WARNER, ESQ. | Attorney | Counsel for CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant counsel | Kristine L. Butler | Attorney | Counsel for CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant counsel | PAUL J. MOLINO | Attorney | Counsel for CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant law firm | Counsel Not Admitted To Usdc (NJ BAR) | Law Firm | Representing CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Defendant law firm | Hill Wallack, LLP | Law Firm | Representing CREEKWOOD PHARMACEUTICALS, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is explicitly procedural — the court’s language directs coordination for ‘pretrial purposes’ and does not adjudicate infringement, validity, or enforceability of any of the six asserted patents. The reference to Civil Action No. 25-12183 as the schedule anchor suggests that case may be the lead docket. No findings on the merits are embedded in this order; the substantive infringement dispute between Supernus and all 14 generic defendants, including Creekwood, remains entirely open.
US12121523B2 — Viloxazine Extended-Release Formulations for ADHD (Qelbree)
The six asserted patents collectively span the full development arc of Supernus’s Qelbree (viloxazine ER) programme, with application dates ranging from US13/761757 (filed 2013) to US17/896774 (filed 2022). The patents cover formulation compositions, extended-release mechanisms, and method-of-use claims for viloxazine — a selective norepinephrine reuptake inhibitor approved for ADHD. The Orange Book listing of all six creates an automatic 30-month stay upon ANDA filing, a foundational Hatch-Waxman exclusivity mechanism that Supernus has employed across its full generic challenger class.
Strategically, a six-patent Orange Book portfolio for a single branded product signals aggressive lifecycle management — each patent layer creates an additional invalidity or non-infringement hurdle for generic applicants. For competitors and generic entrants, the staggered application dates mean patent expiries likely extend across different years, complicating any single-patent design-around strategy. The breadth of the challenger field — 14 defendants — confirms that generic manufacturers see commercial value in viloxazine ER despite the multi-patent barrier, and that at least some believe viable invalidity arguments exist against one or more of the six patents.
Should your team run an FTO against the six Qelbree Orange Book patents?
Any company developing or commercialising viloxazine-based extended-release formulations, novel ADHD CNS therapies, or modified-release oral capsule technologies with overlapping excipient or release-mechanism profiles should treat these six patents as priority FTO targets. The asserted claims span compositions, manufacturing methods, and therapeutic methods — meaning product design, process design, and labelling decisions all fall within potential scope. With 14 ANDA filers already in litigation, the freedom-to-operate landscape for viloxazine ER is actively contested and evolving.
PatSnap Eureka’s FTO Search Agent can map each of the six asserted patents — US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — against your product specifications, identifying claim elements that may read on your formulation or process. Eureka’s claim-level analysis and prior art landscape view lets IP teams prioritise which of the six patents pose the highest risk, and where design-around or IPR petition strategies offer the strongest ROI before committing to ANDA filing or product launch.
Run a freedom-to-operate analysis on US12121523B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Cases: Viloxazine & CNS Extended-Release Formulations
Cases involving Orange Book patent enforcement for CNS extended-release oral formulations in the NJ District Court, including comparable multi-defendant ANDA consolidations.
What this consolidated ANDA battle signals for the CNS pharma IP landscape
Fourteen generic challengers, six Orange Book patents, one consolidated docket — this case is a live stress-test of Supernus’s Qelbree IP estate.
Multi-layer Orange Book portfolios deter but don’t block generic entry
Supernus’s six-patent Orange Book listing for Qelbree reflects a common lifecycle management strategy — stacking formulation and method-of-use patents to extend the litigation runway. Yet 14 generic filers suggest the market sees a viable invalidity or non-infringement path. Companies holding branded CNS assets should audit whether each listed patent is genuinely enforceable, not just strategically positioned.
NJ consolidation practice compresses ANDA timelines for patent holders
The District of New Jersey consolidated this multi-defendant action within 165 days of the first filing, consistent with the court’s active case management culture in Hatch-Waxman matters. Patent holders and generic challengers alike should model ANDA litigation budgets around a single consolidated schedule rather than parallel tracks — the court’s preference here signals efficient, centralised pretrial management.
Supernus v CREEKWOOD — key questions answered
The consolidation order merges Case No. 2:25-cv-13201 with related ANDA infringement actions against 13 other generic defendants for pretrial purposes. It creates a single coordinated schedule and discovery framework. It does not resolve any infringement or validity claims — all substantive disputes remain open and will be adjudicated under the consolidated proceedings anchored to Civil Action No. 25-12183.
Supernus asserted six Orange Book-listed patents: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2. All six relate to Qelbree (viloxazine extended-release capsules) and cover formulation compositions, extended-release mechanisms, and methods of treatment. The patents span application dates from 2013 to 2022.
The consolidation order names 13 additional defendants: Appco Pharma LLC, Somerset Therapeutics LLC, Apotex Inc., Aurobindo Pharma Limited, Aurobindo Pharma U.S.A. Inc., Zydus Lifesciences Global FZE, Zydus Pharmaceuticals (USA) Inc., Zydus Lifesciences Limited, MSN Pharmaceuticals Inc., Zenara Pharma Private Limited, Biophore Pharma Inc., Macleods Pharmaceuticals Ltd., and Macleods Pharma USA Inc. — all ANDA filers for generic viloxazine ER.
Each Orange Book-listed patent triggers an automatic 30-month stay of FDA generic approval upon ANDA filing with a Paragraph IV certification. By listing six patents, Supernus created multiple infringement triggers, each capable of sustaining the stay. Generic entrants must either design around all six, successfully challenge all six, or wait for expiry — materially extending the effective exclusivity window beyond any single patent term.
Under the consolidated schedule referenced in Civil Action No. 25-12183, the parties will proceed through coordinated fact discovery, expert discovery, and likely a Markman (claim construction) hearing. Claim construction rulings will bind all 14 defendants simultaneously. Parties may also file inter partes review petitions at the PTAB, which could trigger a stay of the district court action. No trial date or settlement terms are reflected in the public record at this stage.
PatSnap Eureka searches patents and litigation data to answer instantly.